LEADER 03494oam 2200493 450 001 9910137097803321 005 20230621141108.0 010 $a9782889196258 (ebook) 035 $a(CKB)3710000000824705 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/42688 035 $a(EXLCZ)993710000000824705 100 $a20191103c2015uuuu |u| 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCarbohydrates $ethe yet to be tasted sweet spot of immunity /$fedited by Deirdre R. Coombe and Christopher R. Parish 210 $cFrontiers Media SA$d2015 210 1$aFrance :$cFrontiers Media SA,$d2015 215 $a1 online resource (93 pages) $ccolour illustrations, maps; digital, PDF file(s) 225 1 $aFrontiers Research Topics 320 $aIncludes bibliographical references. 330 $aCarbohydrates are extremely abundant bio-molecules; they are on all mammalian cell surfaces as well as on bacterial cell surfaces. In mammals most secreted proteins are glycosylated, with the glycan component comprising a significant amount by mass of the glycoprotein. Although, many years ago carbohydrate-protein recognition events were demonstrated as involved in invertebrate self-non self recognition, the contribution of carbohydrate-protein binding events to the mechanisms of the mammalian immune response was not embraced with the same enthusiasm. Adaptive immunity and the contribution of antibodies, T cells and T-lymphocyte sub-sets and protein antigen presentation dominated immunological theory. Unlike protein structures, carbohydrate structures are not template driven yet the numerous enzymes involved in carbohydrate biosynthesis and modification are encoded by a major component of the genome, and the expression of these enzymes is tightly regulated. As a consequence carbohydrate structures are also regulated, with different structures appearing according to the stage of cell differentiation and according to the age or health of the individual. The advent of technologies that have allowed carbohydrate structures and carbohydrate-protein binding events to be more easily interrogated has resulted in these types of interactions taking their place in modern immunology. We now know that glycans and their ligands (or lectins) are involved in numerous immunological pathways of both the innate and adaptive systems. However, it is clear that our understanding is still in its infancy, as more and more examples where carbohydrate structures contribute to aspects of the immune response are being recognised. The goal of this research topic is to explore the variety of roles undertaken by glycans and lectins in all aspects of the immune response. The particular focus is how the interactions of glycans with their ligands contribute to the mechanism of immune responses. 517 $aCarbohydrates 606 $aCarbohydrates 610 $aHeparan sulfate 610 $aSiglec 610 $aHIV 610 $asialic acid 610 $ahyaluronan 610 $agalectin 610 $aHeparanase 610 $aInflammation 610 $aglycosaminoglycan 610 $aGlycan 615 0$aCarbohydrates. 700 $aDeirdre R. Coombe$4auth$01363956 702 $aChristopher R. Parish$4auth 801 0$beng 801 2$bUkMaJRU 912 $a9910137097803321 996 $aCarbohydrates$93385038 997 $aUNINA LEADER 05128nam 2201249z- 450 001 9910637781403321 005 20231214133206.0 010 $a3-0365-5611-7 035 $a(CKB)5470000001631723 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/94490 035 $a(EXLCZ)995470000001631723 100 $a20202212d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTargeting the Microbiome for Disease Diagnosis and Therapy$eNew Frontiers for Personalized Medicine 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (280 p.) 311 $a3-0365-5612-5 330 $aBackground: The gut microbiota is emerging as a pivotal player in the pathogenesis of many non-communicable diseases. Thus, it has been proposed as a new diagnostic and therapeutic target.Aim and scope: This Special Issue will focus on the microbiome as a potential target of new personalized therapies or diagnostic tools.History: In recent decades, the gut microbiome has been deeply investigated, and many studies have provided new information on the role of dysbiosis in many gastrointestinal and extra-gastrointestinal diseases. Recently, in addition to its phylogenetic characterization, new information has become available regarding the function of the gut microbiota, thanks to proteomic and metabolomic analyses.Cutting-edge research: The therapeutic modulation of the gut microbiota based on different strategies, including diet modification, antibiotics, prebiotics, probiotics, and, last but not least, fecal microbiota transplantation, has been tested for the treatment of various diseases. Recently, the possible applications and modalities of gut microbiota modulation have been increasingly expanding.We have collected original clinical or pre-clinical research papers and reviews focusing on the use of the microbiome for disease diagnosis, monitoring, or therapy and suggesting new possible gut microbiota-based approaches for personalized care. 517 $aTargeting the Microbiome for Disease Diagnosis and Therapy 606 $aMedicine$2bicssc 610 $aGraves-Basedow's diseases 610 $aHashimoto's thyroiditis 610 $aautoimmunity 610 $agut microbiota 610 $airritable bowel syndrome 610 $amicrobiota 610 $amicrobiome 610 $afood components 610 $anutrients 610 $ahematopoietic stem cell transplantation 610 $afecal microbiota transplantation 610 $aaGvHD 610 $aantibiotic-resistant bacteria 610 $acystic fibrosis 610 $arabbits 610 $aintestinal dysbiosis 610 $afeces microbiome 610 $abeta-blocker 610 $ahemodialysis 610 $anext-generation sequencing 610 $apropensity score matching methods 610 $aviolin plots 610 $arandom sampling 610 $aanalytical reproducibility 610 $afecal matter transplantation 610 $adata disease subtypes 610 $apersonalized medicine 610 $amaltodextrin 610 $adip test 610 $agallstone disease 610 $a16S rDNA gene diversity 610 $ablood biochemical characteristics 610 $amesothelioma 610 $a16S RNA sequencing 610 $aspecies 610 $aprobiotics and gut disease 610 $aprobiotics and acute diverticulitis 610 $aprobiotics and diverticular disease 610 $aprobiotics mechanism of action 610 $aIgA Nephropathy 610 $arifaximin 610 $a?1KI-CD89Tg mice 610 $achildren 610 $aintermittent hypoxemia 610 $aobstructive sleep apnea 610 $atonsil 610 $aweight status 610 $aoral microbiota 610 $arheumatology diseases 610 $abiomarkers 610 $aartificial intelligence 610 $amachine learning 610 $arheumatoid arthritis 610 $aSjogren's syndrome 610 $asystemic lupus erythematosus 610 $aendometrial cancer 610 $aendometrial microbiome 610 $agut microbiome 610 $adysbiosis 610 $aestrogen metabolism 610 $aestrobolome 610 $ainflammation 610 $aantitumour treatment 610 $aprebiotics 610 $aprobiotics 610 $aschizophrenia 610 $adepression 610 $aanxiety 610 $afunctional genes 610 $athymoma 610 $agenera 610 $adriver mutation 610 $acardiovascular diseases 610 $acritically ill 610 $aintestinal permeability 610 $arecurrent cystitis 615 7$aMedicine 700 $aLaterza$b Lucrezia$4edt$01285497 702 $aLaterza$b Lucrezia$4oth 906 $aBOOK 912 $a9910637781403321 996 $aTargeting the Microbiome for Disease Diagnosis and Therapy$93019608 997 $aUNINA